Y Intercept Hong Kong Ltd Has $248,000 Position in Kiniksa Pharmaceuticals International, plc $KNSA

Y Intercept Hong Kong Ltd decreased its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 89.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,395 shares of the company’s stock after selling 53,169 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Kiniksa Pharmaceuticals International were worth $248,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Amundi acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC lifted its holdings in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $233,000. Finally, Nordea Investment Management AB increased its position in Kiniksa Pharmaceuticals International by 1.6% during the 2nd quarter. Nordea Investment Management AB now owns 130,160 shares of the company’s stock worth $3,582,000 after buying an additional 2,110 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

KNSA has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.33.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 20,129 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. The trade was a 61.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 42,841 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the completion of the transaction, the chief financial officer directly owned 31,086 shares of the company’s stock, valued at approximately $1,289,758.14. The trade was a 57.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 135,548 shares of company stock valued at $5,675,604. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $42.58 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $18.12 and a 1 year high of $45.50. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of 94.62 and a beta of 0.06. The company’s 50 day simple moving average is $41.80 and its 200 day simple moving average is $38.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same period in the prior year, the business posted ($0.18) EPS. The company’s revenue for the quarter was up 61.2% compared to the same quarter last year. As a group, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.